A Steady Rise in the Filing of Onglyza Lawsuits

A Steady Rise in the Filing of Onglyza Lawsuits

Introduction

With more than 80 product liability lawsuits already pending in the federal court, Onglyza MDL No. 2809 is witnessing a steady rise in the number of lawsuits as expected. Centralization took place in February this year with the U.S. District Court for the Eastern District of Kentucky chosen as the venue for trial proceedings under District Judge Karen K. Caldwell. Lawsuits have been filed by individuals who developed congestive heart failure and other side effects naming Bristol-Myers Squibb and AstraZeneca as the defendants for not providing adequate warnings about the severe side-effects linked to this diabetic drug. A recent lawsuit was filed in the U.S. District Court for the Southern District of Ohio by the family of an Ohio man who claims that the use of Onglyza and Kombiglyze XR led to the development of heart failure, congestive heart failure, and cardiovascular injury.

Another Onglyza lawsuit was filed by a Kentucky woman in the U.S. District Court for the Southern District of New York alleging she suffered heart failure, congestive heart failure, and cardiovascular injury. Her case will join the growing number of lawsuits filed against the drug manufacturers to be a part of the coordinated pretrial proceedings under District Judge Karen K. Caldwell.